Alisa A. Acosta, MD, MPHAsst. Professor, Renal Section
April 5, 2019
Pediatric Hypertension
Page 1
xxx00.#####.ppt 4/3/19 10:21:07 AM
Objectives
• Recognize the importance of accurate blood pressure measurement in pediatric patients
• Define pediatric hypertension (HTN) according to the 2017 AAP Clinical Practice Guidelines
• Evaluate a pediatric patient with HTN
• Manage basic pediatric HTN
Page 2
xxx00.#####.ppt 4/3/19 10:21:08 AM
Page 3
xxx00.#####.ppt 4/3/19 10:21:09 AM
Absolute Risk for Ischemic Heart Disease Mortality –Systolic BP
(Graph looks similar for stroke risk)
Adult Data
Lancet 2002; 360: 1903-13
Page 4
xxx00.#####.ppt 4/3/19 10:21:09 AM
HTN in Adults• Almost one in three adults has HTN (32.6%)
- Almost half don’t know it (17.2%)- Almost 46% are under-treated
• Lowering BP in adults with Stage 1 HTN leads to a reduction in the incidence of:- Myocardial infarctions (20-25%)- Stroke (35-40%)- Heart Failure (>50%) - AND overall mortality (~10% at 10 years)
Mozaffarian D et al, Circulation 2016;133:447-454
Chobanian, Hypertension 2003;42:1206-52
Page 5
xxx00.#####.ppt 4/3/19 10:21:10 AM
Pediatric Hypertension
• Generally healthy children with primary HTN do not suffer from CV end points seen in adults
• Children with elevated BP are likely to become adults with hypertension
• Prevention, early detection, and appropriate treatment for those at risk is the way to eliminate the burden of this disease
Page 6
xxx00.#####.ppt 4/3/19 10:21:11 AM
History of Hypertension in Pediatrics• Before 1977: no accepted normative data
• 1977: 1st Task Force Report (3 sources)
- Normative data for children
- Defined HTN >95th percentile for age & gender
• 1987: 2nd Task Force Report (9 sources)
- Additional data for over 60,000 children
- Improved racial mix
• 1996: Task Force Update
- Incorporated height in the BP norms
• 2004: Fourth Working Group Report
• 2017: AAP Clinical Practice Guidelines (CPG)
Page 7
xxx00.#####.ppt 4/3/19 10:21:11 AM
http://pediatrics.aappublications.org/content/early/2017/08/21/peds.2017-1904
Page 8
xxx00.#####.ppt 4/3/19 10:21:12 AM
Table 1Summary of KAS for Screening and Management of High BP in Children and Adolescents
Page 9
xxx00.#####.ppt 4/3/19 10:21:13 AM
Table 11Patient Evaluation & Management According to BP Level
Page 10
xxx00.#####.ppt 4/3/19 10:21:14 AM
Classification of BP – Children
Page 11
xxx00.#####.ppt 4/3/19 10:21:15 AM
-2 -1 0 1 2
5%
z = +1.65
95%
Epidemiologic Definition
Page 12
xxx00.#####.ppt 4/3/19 10:21:16 AM
Who should have BP measured
• Children ≥3 years old should have BP measured annually
• Children ≥3 yrs at every health care encounter if meds/conditions increase risk for HTN
• Children < 3 years should have BP measured under special circumstances
Page 13
xxx00.#####.ppt 4/3/19 10:21:17 AM
Special Circumstances for Children < 3 years old
- Prematurity <32 wks or SGA, VLBW, other
- Congenital heart disease
- Renal disease or urologic malformation
• Recurrent UTI, hematuria, proteinuria
• FH of congenital renal disease
- Solid-organ transplant
- Malignancy or BMT
- Tx with meds known to raise BP
- Other systemic illnesses a/w HTN (NF, TS)
- Evidence of elevated intracranial pressure
Page 14
xxx00.#####.ppt 4/3/19 10:21:17 AM
Page 15
xxx00.#####.ppt 4/3/19 10:21:18 AM
Four Clinical Questions
1. Does my patient have hypertension?2. Why does my patient have hypertension?3. Is there any evidence of target organ
damage?4. Are there any other modifiable risk
factors for CVD?
Page 16
xxx00.#####.ppt 4/3/19 10:21:19 AM
Case 1
• A 7 year old boy comes to your office for a well child check. Ht is 25th% and wt is >95th%. In triage using a machine and a child cuff, his blood pressure measures 117/78. His history and exam are normal.
• Does he have an elevated blood pressure?
Page 17
xxx00.#####.ppt 4/3/19 10:21:19 AM
50th%ile - 94/56
90th%ile - 107/6895th%ile - 110/7195th+12 - 122/83
Pt’s BP: 117/78
Page 18
xxx00.#####.ppt 4/3/19 10:21:21 AM
Dilemma of BP Measurement
• Norms based on auscultatory measurements with mercury manometers
• Oscillometric monitors are largely used- Poor correlation with auscultatory methods- Measure the MAP, calculates SBP & DBP using
proprietary, unpublished algorithms• BP > 90th percentile by oscillometric devices
should be repeated by auscultation
Page 19
xxx00.#####.ppt 4/3/19 10:21:21 AM
BP Measurement
•Properly positioned-Seated-Back Supported-Feet on the floor-Arm resting at heart level
•After 5 mins of rest
•Empty bladder
•Avoidance of stimulant drugs or foods 30 mins prior
Page 20
xxx00.#####.ppt 4/3/19 10:21:22 AM
Proper Cuff Size
•Small cuffs over-
estimate BP more
than large cuffs
under-estimate BP
•Between sizes,
choose the larger
cuff
Page 21
xxx00.#####.ppt 4/3/19 10:21:23 AM
Case 1
• You re-measure the blood pressure by auscultation after at least 5 minutes of rest. You measure the arm circumference to be 32 cm.
• Child cuff 15-29 cm• Adult cuff 29-42 cm
Page 22
xxx00.#####.ppt 4/3/19 10:21:23 AM
After changing to an adult cuff, his blood pressure was recorded as 105/67
50th%ile - 94/56
90th%ile - 107/6895th%ile - 110/71
95th+12 - 122/83
Pt’s Original BP: 117/78
Page 23
xxx00.#####.ppt 4/3/19 10:21:25 AM
Does this patient have hypertension?
no
Page 24
xxx00.#####.ppt 4/3/19 10:21:25 AM
Case 2
• A 14 yr old boy has multiple visits with an elevated blood pressure ranging from the 130s-143/ 70s-90 measured by auscultation with an appropriate sized cuff
• Height and weight =95th percentile• Remainder of his history and physical exam is
benign, and there is no family history of hypertension
Page 25
xxx00.#####.ppt 4/3/19 10:21:26 AM
Does this patient have hypertension?
Patient’s BP = 130s-143/ 70s-90s
Page 26
xxx00.#####.ppt 4/3/19 10:21:27 AM
Is clinic BP the best measure?
• 24 hr Ambulatory Blood Pressure Monitoring
• Useful in the evaluation of- White coat hypertension- Apparent drug resistant hypertension
- Evaluation of drug-induced hypotension
• Provides an overall BP pattern- BP load- Nocturnal BP
Page 27
xxx00.#####.ppt 4/3/19 10:21:27 AM
24 hr Ambulatory BP Monitoring• White-Coat Hypertension
- Clinic BP is high but ambulatory BP (ABP) is normal- Prevalence in children is up to 62%, probably 20%- “Pre-hypertensive state?”
• Masked Hypertension- Clinic BP is normal but the ABP is elevated- Occurs in ~10% of youth- Same risk for CVD as those with sustained HTN
Page 28
xxx00.#####.ppt 4/3/19 10:21:28 AM
Case 2: 24 hr ABPMSystolic BPMean Arterial PressureDiastolic BP
Page 29
xxx00.#####.ppt 4/3/19 10:21:29 AM
130 mmHg77 mmHg
95th %ile
Page 30
xxx00.#####.ppt 4/3/19 10:21:29 AM
Does this patient have hypertension?technically, no – white
coat HTN
Page 31
xxx00.#####.ppt 4/3/19 10:21:30 AM
Case 3
• An 8 yr old boy had an elevated mean BP by auscultation with an appropriate sized cuff on 3 separate occasions: 148/78, 154/90, 142/81
• Asymptomatic, no significant PMH. MGM has HTN• Wt 34.5kg (75%), Ht 131.5cm (25%), BMI 20.6 (90%)
• BP in RLE 103/72
• Exam is benign but difficult to palpate LE pulses
Page 32
xxx00.#####.ppt 4/3/19 10:21:31 AM
Does this patient have hypertension?148/78, 154/90, 142/81
90th%ile – 110/72
95th%ile – 114/77
99th%ile – 122/85
Yes,Stage II
Why does he have hypertension?
Case 3
Page 33
xxx00.#####.ppt 4/3/19 10:21:31 AM
Evaluation for Secondary HTN
• Secondary hypertension is more common in children
• The younger the child and /or the more severe the hypertension, the more likely there is a secondary cause
Page 34
xxx00.#####.ppt 4/3/19 10:21:32 AM
Causes of Hypertension• Renal parenchymal disease
- Congenital anomalies of the urinary tract- Glomerulonephritis- Polycystic kidney disease- Sequelae of acute kidney injury, i.e. HUS- Chronic kidney disease- Systemic vasculitis with renal involvement
• Renovascular defect- Fibromuscular dysplasia- Midaortic syndrome- Renal vein thrombosis
Page 35
xxx00.#####.ppt 4/3/19 10:21:32 AM
Causes of Hypertension
• Coarctation of the aorta• Pulmonary
- Chronic lung disease of the newborn
• Monogenic forms- AME- Liddle’s syndrome- Gordon’s syndrome- GRA
• Renal Tumors
• Endocrine- Catecholamine excess
• Pheochromocytoma• Paraganglioma• Neuroblastoma
- Cushing syndrome- Hyperaldosteronism- Thyroid disorders- Congenital adrenal
hyperplasia- Hypercalcemia
Page 36
xxx00.#####.ppt 4/3/19 10:21:33 AM
Initial Evaluation
Page 37
xxx00.#####.ppt 4/3/19 10:21:34 AM
Initial Evaluation• Thorough history and physical exam
• Electrolytes, BUN, creatinine• CBC
• +/- Thyroid function studies
• Urinalysis +/- urine cx• Renal ultrasound
- Scars
- Congenital anomaly
- Discordant kidney size
Page 38
xxx00.#####.ppt 4/3/19 10:21:35 AM
Further Evaluation• Renovascular imaging• Plasma renin• Plasma and urine steroid levels• Plasma and urine catecholamines
Page 39
xxx00.#####.ppt 4/3/19 10:21:36 AM
Case 3• Normal renal ultrasound
• Normal urinalysis• Normal electrolytes, BUN, Cr
• Normal thyroid function tests
• Echocardiogram- Functional bicuspid aortic valve
- Distal aortic arch appeared narrowed
- Abdominal Doppler suggested mild obstruction
- Mild concentric left ventricular hypertrophy
Page 40
xxx00.#####.ppt 4/3/19 10:21:37 AM
Four Clinical Questions
1. Does my patient have hypertension?
2. Why does my patient have hypertension?
Yes
Coarctation of the aorta
Page 41
xxx00.#####.ppt 4/3/19 10:21:37 AM
Case 4
• 11 yr old female, elevated BP by auscultation on multiple occasions, 126-130/78-89, confirmed by ABPM
• She is asymptomatic. Mom and maternal grandparents have hypertension.
• Negative PMH• Wt 91.4kg (>97%), Ht 160.9cm (>97%), BMI 35.3kg/m2 (>95%)• Exam is unremarkable including 4 extremity BP
Page 42
xxx00.#####.ppt 4/3/19 10:21:38 AM
Four Clinical Questions
1. Does my patient have hypertension?
2. Why does she have hypertension?
Yes, stage I
90th%ile – 120/77
95th%ile – 124/8199th%ile – 131/89
126-130/78-89
Page 43
xxx00.#####.ppt 4/3/19 10:21:38 AM
Case 4
• Normal urinalysis• Normal electrolytes, BUN, Cr• Normal thyroid function tests• Normal renal ultrasound (not indicated)
Page 44
xxx00.#####.ppt 4/3/19 10:21:39 AM
Four Clinical Questions
1. Does my patient have hypertension?
2. Why does my patient have hypertension?
Yes
Primary hypertension, likely obesity-related, family history, etc.
Page 45
xxx00.#####.ppt 4/3/19 10:21:40 AM
The Obesity Epidemic
Page 46
xxx00.#####.ppt 4/3/19 10:21:41 AM
Prevalence of Obesity* Among US Children and Adolescents (aged 2 – 19 years)
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
NHANES II 1976-1980 NHANES III 1988-1994 NHANES 1999-2002 NHANES 2003-2006
Ages 2 - 5 Ages 6 - 11 Ages 12 - 19 www.cdc.gov
*age and sex-specific BMI ≥ 95th percentile
Page 47
xxx00.#####.ppt 4/3/19 10:21:41 AM
Hypertension follows Obesity
Distribution of BMI percentiles and the prevalence of HTN within each BMI percentile category
Sorof et al, J Pediatr 2002;140:660-6
Page 48
xxx00.#####.ppt 4/3/19 10:21:43 AM
Four Clinical Questions
1. Does my patient have hypertension?
2. Why does my patient have hypertension?
3. Is there any evidence of target organ damage?
Yes
Likely obesity-related, family history
Page 49
xxx00.#####.ppt 4/3/19 10:21:43 AM
Target Organ Damage•Measurable abnormalities attributed to HTN that occur before significant cardiovascular events
-Microalbuminuria or overt proteinuria
-Hypertensive retinopathy
-Left ventricular hypertrophy
-Increased carotid artery intima media thickness
-Decreased vascular compliance
Page 50
xxx00.#####.ppt 4/3/19 10:21:44 AM
Left Ventricular Hypertrophy
•Most prominent evidence of target organ damage- Echocardiography should be performed at the
time of consideration of pharmacologic therapy
- Monitored every 6 -12 months
Page 51
xxx00.#####.ppt 4/3/19 10:21:45 AM
Four Clinical Questions1. Does my patient have hypertension?
2. Why does my patient have hypertension?
3. Is there any evidence of target organ damage?
4. Are there any other modifiable risk factors for CVD?
Yes
Likely obesity-related, family history
Yes, LVH on echocardiogram
Page 52
xxx00.#####.ppt 4/3/19 10:21:45 AM
Evaluation for Co-morbidities•Fasting labs
-Lipid panel
-Hgb A1c
-AST, ALT
•If indicated:-Drug Screen
-TSH
-CBC
-Polysomnography•Snoring or other symptoms of sleep disorded breathing
•Nocturnal hypertension
Page 53
xxx00.#####.ppt 4/3/19 10:21:46 AM
Case 4
• Fasting labs- Normal lipid panel - Normal Hgb A1c
• Sleep Study- Obstructive sleep apnea- Treated with CPAP
Page 54
xxx00.#####.ppt 4/3/19 10:21:47 AM
Four Clinical Questions1. Does my patient have hypertension?
2. Why does my patient have hypertension?
3. Is there any evidence of target organ damage?
4. Are there any other modifiable risk factors for CVD?
Yes
Likely obesity-related, family history
Yes, LVH on echocardiogram
Several: wt management, insulin resistance, sleep apnea
How should I treat my patient’s hypertension?
Now what?
Page 56
xxx00.#####.ppt 4/3/19 10:21:48 AM
Meds or no meds?
• Therapeutic lifestyle changes initiated in all patients- Healthy eating- Regular cardiovascular exercise - Good sleeping habits
• Family-based intervention improves success• Avoid stimulant medications when possible
Page 57
xxx00.#####.ppt 4/3/19 10:21:49 AM
Weight Loss
• Indicated in obesity-related HTN• Weight loss improves
- BP in overweight adolescents- Salt sensitivity of BP - Decreases other cardiovascular risk factors
• Dyslipidemia• Insulin resistance
Page 58
xxx00.#####.ppt 4/3/19 10:21:49 AM
Page 59
xxx00.#####.ppt 4/3/19 10:21:50 AM
Sodium Restriction
• Increased sodium intake is associated with
higher BP at all ages
• Current Recommendations
- 4-8 year olds – 1.2 g/day
- > 8 years – 1.5 g/day
Page 60
xxx00.#####.ppt 4/3/19 10:21:51 AM
Page 61
xxx00.#####.ppt 4/3/19 10:21:51 AM
Physical Activity
• Regular physical activity is beneficial for preventing and treating HTN in adults
• In children- Inverse relationship between fitness and SBP- Improved fitness slows the progression of
elevated BP at one year- Studies suggest an effect of exercise on BP
reduction independent of weight loss
Page 62
xxx00.#####.ppt 4/3/19 10:21:52 AM
Indications for Pharmacotherapy
• Symptomatic hypertension• Secondary hypertension• Stage 2 hypertension • Target organ damage• Diabetes (types 1 and 2), CKD• Persistent hypertension despite
nonpharmacologic measures
Page 63
xxx00.#####.ppt 4/3/19 10:21:53 AM
Pharmacotherapy
• Clinical trials have expanded the number of drugs with pediatric dosing
• Pharmacotherapy should be initiated with a single drug
• Goal is a reduction of BP to <95th percentile- Goal of <90th percentile if concurrent conditions
are present
PharmacotherapyACE inhibitor Benazepril, Captopril, Enalapril,
Fosinopril, Lisinopril, Quinapril
Angiotensin-receptor blocker Irbesartan, Losartan, Valsaratan,Telmisartan
α- and β-antagonist Labetalol
β-antagonist Atenolol, Bisoprolol/HCTZ, Metoprolol, Propranolol
Calcium channel blocker Amlodipine, Felodipine, IsradipineExtended-release nifedipine
Central α- agonist Clonidine
Diuretic Furosemide, HCTZ, Amiloride Spironolactone, TriamtereneChlorthalidone
Peripheral α- antagonist Doxazosin, Prazosin, Terazosin
Vasodilator Hydralazine, Minoxidil
Page 65
xxx00.#####.ppt 4/3/19 10:21:53 AM
Choosing a Medication• Based on benefit/side effect profile, availability,
and ease of administration • No evidence HCTZ should be first line agent• Racial differences in response to various drug
classes have yet to be shown• Maximize the dose of single agent before adding
additional agents
Page 66
xxx00.#####.ppt 4/3/19 10:21:54 AM
Choosing a Medication
• Calcium channel blockers are generally safe first line agents while awaiting evaluation
• Beta blockers- Avoid the use in asthma patients- Preferred drug if history of migraine HA
• Avoid ACEi and ARB until renal evaluation is complete
Page 67
xxx00.#####.ppt 4/3/19 10:21:55 AM